Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11616844 | 0.94 | SMN1; SMN2 (0.42) | HPGDHTTSMN1; SMN2LMNAPOLB | |
| SCHEMBL29110915 | 0.87 | — | — | |
| SCHEMBL27141183 | 0.87 | — | — | |
| SCHEMBL7469238 | 0.80 | ALDH1A1 (0.37) | HPGDHTTSMN1; SMN2LMNAPOLB | |
| SCHEMBL30509807 | 0.79 | PKM (0.36) | HPGDHTTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL4770390 | 0.79 | ALDH1A1 (0.36) | HPGDHTTSMN1; SMN2LMNAPOLB | |
| SCHEMBL1272645 | 0.79 | ALDH1A1 (0.36) | HPGDHTTSMN1; SMN2LMNAPOLB | |
| SCHEMBL7321280 | 0.79 | ALDH1A1 (0.36) | HPGDHTTSMN1; SMN2LMNAPOLB | |
| SCHEMBL14647288 | 0.79 | PKM (0.36) | HPGDHTTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL13486886 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070106083-A1 | Process for preparing 4-aminotetrahydropyran compound and an acid salt thereof, synthetic intermediate thereof and process for preparing the same | UBE INDUSTRIES, LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1661894-A1 | PROCESS FOR PRODUCTION OF 4-AMINOTETRAHYDROPYRANS AND SALTS THEREOF WITH ACIDS, INTERMEDIATES FOR THE PROCESS, AND PROCESS FOR PRODUCTION THEREOF | Ube Industries, Ltd. (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106083-A1 | Process for preparing 4-aminotetrahydropyran compound and an acid salt thereof, synthetic intermediate thereof and process for preparing the same | PAH, HPD, REN | HPGD 33/4885HTT 202/4885SMN1; SMN2 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.